adriblastina pfs 2 mg/ml roztwór do wstrzykiwań
pfizer europe ma eeig - doxorubicini hydrochloridum - roztwór do wstrzykiwań - 2 mg/ml
adriblastina r.d. 10 mg proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
pfizer europe ma eeig - doxorubicini hydrochloridum - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 10 mg
adriblastina r.d. 50 mg proszek do sporządzania roztworu do wstrzykiwań
pfizer europe ma eeig - doxorubicini hydrochloridum - proszek do sporządzania roztworu do wstrzykiwań - 50 mg
doxorubicin-ebewe 2 mg/ml koncentrat do sporządzania roztworu do infuzji
ebewe pharma ges.m.b.h nfg. kg - doxorubicini hydrochloridum - koncentrat do sporządzania roztworu do infuzji - 2 mg/ml
doxorubicinum accord 2 mg/ml koncentrat do sporządzania roztworu do infuzji
accord healthcare polska sp. z o.o. - doxorubicini hydrochloridum - koncentrat do sporządzania roztworu do infuzji - 2 mg/ml
doxorubicin medac 2 mg/ml roztwór do infuzji
medac gesellschaft für klinische spezialpräparate mbh - doxorubicini hydrochloridum - roztwór do infuzji - 2 mg/ml
doxorubicin actavis 2 mg/ml koncentrat do sporządzania roztworu do infuzji
actavis group ptc ehf. - doxorubicini hydrochloridum - koncentrat do sporządzania roztworu do infuzji - 2 mg/ml
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - chlorowodorek doksorubicyny - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Środki przeciwnowotworowe - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
yondelis
pharma mar s.a. - trabektedyna - ovarian neoplasms; sarcoma - Środki przeciwnowotworowe - yondelis jest wskazany w leczeniu pacjentów z zaawansowanym mięsakiem tkanek miękkich, po niepowodzeniu antracyklin i ifosfamidu, lub którzy nie nadają się do przyjmowania tych leków. dane dotyczące skuteczności opierają się głównie na pacjentach z mięsakiem liposiarczanowym i mięsakami gładkokomórkowymi. Йонделис w połączeniu z pegylowany липосомальным doksorubicyną (plis) jest wskazany do leczenia pacjentów z nawracającym platynowo-wrażliwy na raka jajnika .